Pharmaceutical and Biosciences

Our pharmaceutical and biosciences team brings together a broad range of legal expertise to deliver comprehensive advice to local and international clients engaged in various aspects of this sector – from early stage medical research to managing participation in the pharmaceutical and medical device industries.

Our lawyers advise on intellectual property licensing, protection and disputes, regulation of bioscience research including clinical trial requirements and management of claims arising from adverse outcomes, regulation of pharmaceutical and medical device products including Therapeutic Goods Administration requirements, insurance requirements, compliance with industry standards and issues relating to inclusion on the Pharmaceutical Benefits Scheme and the Prosthesis List. We also advise on commercialisation techniques, venture capital investments, R & D tax concessions, effective tax effective structuring and IPOs.

We also have an affinity with and understanding of the science involved – many of our lawyers and consultants are qualified in science-related disciplines such as biochemistry, neuroscience, computing, mathematics, genetics and molecular biology.

We have advised on some of the largest, most complex transactions in the pharmaceutical industry and have had extensive involvement in bioscience research projects. Our work has included preparing and negotiating agreements for research collaborations, joint ventures, consultancy agreements, funding agreements, manufacturing and supply agreements, confidentiality agreements and material transfer agreements.

A$888 million underwritten placement and pro-rata accelerated non-renounceable entitlement offer

Advised Mayne Pharma Group Limited in relation to its A$888 million underwritten placement and pro-rata accelerated non-renounceable entitlement offer.

Sale of Spinifex Pharmaceuticals to Novartis AG

Acted for Spinifex Pharmaceuticals (Spinifex) and its major shareholder Brandon Capital in the sale of Spinifex to Swiss based pharmaceutical giant Novartis AG (Novartis). MinterEllison acted for Brandon Capital in relation to its original investment into Spinifex through the Brandon Biosciences Fund as well as the MRCF Collaboration.